Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious ...
BOSTON & MONTREAL, November 11, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback